HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.

By FierceBiotech · May 11, 2026 · via FierceBiotech
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
moneyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
MoneyFiercePharma ↗
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
May 11, 2026
Optimi Health’s IPO Rides Psychedelics Policy Shift
MoneyBriefing
Optimi Health’s IPO Rides Psychedelics Policy Shift
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…
May 11, 2026
CSL sinks to nine-year low on revenue warning, $5B write-down
MoneyEndpoints News ↗
CSL sinks to nine-year low on revenue warning, $5B write-down
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by…
May 11, 2026